Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.19.8177

Efficacy and Toxicity of Anti-VEGF Agents in Patients with Castration-Resistant Prostate Cancer: a Meta-analysis of Prospective Clinical Studies  

Qi, Wei-Xiang (Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center)
Fu, Shen (Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center)
Zhang, Qing (Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center)
Guo, Xiao-Mao (Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.19, 2014 , pp. 8177-8182 More about this Journal
Abstract
Background: Blocking angiogenesis by targeting vascular endothelial growth factor (VEGF) signaling pathway to inhibit tumor growth has proven to be successful in treating a variety of different metastatic tumor types, including kidney, colon, ovarian, and lung cancers, but its role in castration-resistant prostate cancer (CRPC) is still unknown. We here aimed to determine the efficacy and toxicities of anti-VEGF agents in patients with CRPC. Materials and Methods: The databases of PubMed, Web of Science and abstracts presented at the American Society of Clinical Oncology up to March 31, 2014 were searched for relevant articles. Pooled estimates of the objective response rate (ORR) and prostate-specific antigen (PSA) response rate (decline ${\geq}50%$) were calculated using the Comprehensive Meta-Analysis (version 2.2.064) software. Median weighted progression-free survival (PFS) and overall survival (OS) time for anti-VEGF monotherapy and anti-VEGF-based doublets were compared by two-sided Student's t test. Results: A total of 3,841 patients from 19 prospective studies (4 randomized controlled trials and 15 prospective nonrandomized cohort studies) were included for analysis. The pooled ORR was 12.4% with a higher response rate of 26.4% (95%CI, 13.6-44.9%) for anti-VEGF-based combinations vs. 6.7% (95%CI, 3.5-12.7%) for anti-VEGF alone (p=0.004). Similarly, the pooled PSA response rate was 32.4% with a higher PSA response rate of 52.8% (95%CI: 40.2-65.1%) for anti-VEGF-based combinations vs. 7.3% (95%CI, 3.6-14.2%) for anti-VEGF alone (p<0.001). Median PFS and OS were 6.9 and 22.1 months with weighted median PFS of 5.6 vs. 6.9 months (p<0.001) and weighted median OS of 13.1 vs. 22.1 months (p<0.001) for anti-VEGF monotherapy vs. anti-VEGF-based doublets. Conclusions: With available evidence, this pooled analysis indicates that anti-VEGF monotherapy has a modest effect in patients with CRPC, and clinical benefits gained from anti-VEGF-based doublets appear greater than anti-VEGF monotherapy.
Keywords
VEGF inhibitors; angiogenesis inhibitors; castration-resistant prostate cancer; efficacy;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999). Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet, 354, 1896-900   DOI   ScienceOn
2 Motzer RJ, Escudier B, Tomczak P, et al (2013a). Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol, 14, 552-62   DOI
3 Motzer RJ, Hutson TE, Cella D, et al (2013b). Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med, 369, 722-31   DOI
4 Perren TJ, Swart AM, Pfisterer J, et al (2011). A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med, 365, 2484-96   DOI
5 Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006). Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 295, 2516-24   DOI   ScienceOn
6 Mukherji D, Temraz S, Wehbe D, Shamseddine A (2013). Angiogenesis and anti-angiogenic therapy in prostate cancer. Crit Rev Oncol Hematol, 87, 122-31   DOI
7 Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008). Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA, 300, 2277-85   DOI   ScienceOn
8 Qi WX, He AN, Shen Z, Yao Y (2013a). Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and metaanalysis. Br J Clin Pharmacol, 76, 348-57   DOI
9 Qi WX, Lin F, Sun YJ, et al (2013b). Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol , 71, 431-9   DOI
10 Qi WX, Min DL, Shen Z, et al (2013c). Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer, 132, 2967-74   DOI
11 Qi WX, Shen Z, Lin F, et al (2013d). Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol, 75, 919-30   DOI
12 Qi WX, Shen Z, Tang LN, Yao Y (2014). Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis. Clin Drug Investig, 34, 231-40   DOI
13 Ryan CJ, Small EJ (2003). Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology , 62, 87-94   DOI
14 Qi WX, Shen Z, Yao Y (2011a). Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials. J Cancer Res Clin Oncol, 137, 1785-90   DOI
15 Qi WX, Tang LN, He AN, Shen Z, Yao Y (2011b). The role of vandetanib in the second-line treatment for advanced nonsmall-cell-lung cancer: a meta-analysis of four randomized controlled trials. Lung, 189, 437-43   DOI
16 Qi WX, Tang LN, Sun YJ, et al (2013e). Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date metaanalysis of 27 randomized controlled trials. Ann Oncol, 24, 2943-52   DOI
17 Schutz FA, Jardim DL, Je Y, Choueiri TK (2011a). Haematologic toxicities associated with the addition of bevacizumab in cancer patients. Eur J Cancer, 47, 1161-74   DOI   ScienceOn
18 Sandler A, Gray R, Perry MC, et al (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 355, 2542-50   DOI   ScienceOn
19 Santoni M, Conti A, De Giorgi U, et al (2013). Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials. Int J Cancer, 135, 763-73.
20 Scappaticci FA, Skillings JR, Holden SN, et al (2007). Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst, 99, 1232-9   DOI   ScienceOn
21 Schutz FA, Je Y, Choueiri TK (2011b). Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. Crit Rev Oncol Hematol, 80, 291-300   DOI   ScienceOn
22 Wu Y, Rosenberg JE, Taplin ME (2011). Novel agents and new therapeutics in castration-resistant prostate cancer. Curr Opin Oncol, 23, 290-6   DOI
23 Van Cutsem E, Tabernero J, Lakomy R, et al (2012). Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol, 30, 3499-506   DOI
24 Wang K, Peng HL, Li LK (2012). Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: a systematic review with meta-analysis. Asian Pac J Cancer Prev, 13, 5665-9   DOI   ScienceOn
25 Aragon-Ching JB, Dahut WL (2009). VEGF inhibitors and prostate cancer therapy. Curr Molec Pharmacol, 2, 161-8   DOI
26 Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol, 143, 401-9
27 Yang JC, Haworth L, Sherry RM, et al (2003). . A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 349, 427-34   DOI   ScienceOn
28 Zintzaras E, Ioannidis JP (2005). Heterogeneity testing in metaanalysis of genome searches. Genet Epidemiol, 28, 123-37   DOI   ScienceOn
29 Beardsley EK, Hotte SJ, North S, et al (2012). A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Invest New Drugs, 30, 1652-9   DOI
30 Abou-Alfa GK, Schwartz L, Ricci S, et al (2006). Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 24, 4293-300   DOI   ScienceOn
31 Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME (2011). The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs
32 Bok RA, Halabi S, Fei DT, et al (2001). Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res, 61, 2533-6
33 Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101   DOI   ScienceOn
34 Belum VR, Wu S, Lacouture ME (2013). Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs
35 Berthold DR, Pond GR, Soban F, et al (2008). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol, 26, 242-5   DOI   ScienceOn
36 Borre M, Bentzen SM, Nerstrom B, Overgaard J (1998a). Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol, 159, 1609-14   DOI   ScienceOn
37 Di Lorenzo G, Figg WD, Fossa SD, et la (2008). Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol, 54, 1089-94   DOI   ScienceOn
38 Borre M, Offersen BV, Nerstrom B, Overgaard J (1998b). Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer, 78, 940-4   DOI   ScienceOn
39 Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J (2010). Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol, 28, 2280-5   DOI   ScienceOn
40 Chu D, Lacouture ME, Weiner E, Wu S (2009). Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer, 7, 11-9   DOI   ScienceOn
41 Ferrara N, Davis-Smyth T (1997). The biology of vascular endothelial growth factor. Endocrine reviews, 18, 4-25   DOI
42 Duque JL, Loughlin KR, Adam RM, et al (1999). Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology, 54, 523-7   DOI   ScienceOn
43 Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629-34   DOI   ScienceOn
44 Eisenberger MA, Walsh PC (1999). Early androgen deprivation for prostate cancer? N Engl J Med, 341, 1837-8   DOI   ScienceOn
45 Fischer A, Wu S, Ho AL, Lacouture ME (2013). The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs
46 Grothey A, Van Cutsem E, Sobrero A, et al (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381, 303-12   DOI   ScienceOn
47 Folkman J (2002). Role of angiogenesis in tumor growth and metastasis. Seminars in oncology, 29, 15-8
48 Folkman J (2006). Angiogenesis. Ann Rev Med, 57, 1-18   DOI   ScienceOn
49 Funakoshi T, Latif A, Galsky MD (2013). Risk of hematologic toxicities in cancer patients treated with sunitinib: A systematic review and meta-analysis. Cancer Treat Rev, 39, 818-30.   DOI
50 Gustavsson H, Welen K, Damber JE (2005). Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate, 62, 364-73   DOI
51 Je Y, Schutz FA, Choueiri TK (2009). Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol, 10, 967-74   DOI   ScienceOn
52 Hicklin DJ, Ellis LM (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 23, 1011-27
53 Jia Y, Lacouture ME, Su X, Wu S (2009). Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol, 7, 211-7
54 Hurwitz H, Fehrenbacher L, Novotny W, et la (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, 2335-42   DOI   ScienceOn
55 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90   DOI
56 Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ (2013). Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clin Oncol, 25, 406-30   DOI
57 Merino M, Pinto A, Gonzalez R, Espinosa E (2011). Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer. Eur J Cancer, 47, 1846-51   DOI